Core Insights - Vasomune Therapeutics Inc. and AnGes Inc. have expanded their co-development agreement to include additional indications for the Tie2 receptor agonist Pegevongitide (AV-001) [1][2] - The expanded research will explore Pegevongitide's potential in treating conditions beyond Acute Respiratory Distress Syndrome, including cognitive impairment associated with hemodialysis [2] Company Overview - Vasomune Therapeutics is a private clinical-stage biopharmaceutical company founded in 2014, focusing on developing medicines to enhance the body's defense against vascular leak [4] - The company has advanced Pegevongitide (AV-001) from preclinical stages to clinical trials, targeting various diseases linked to vascular dysfunction [4] - AnGes Inc., established in December 1999, specializes in gene-based medicines and is developing AV-001 for pneumonia and other conditions [6] Financial and Developmental Aspects - The expanded agreement provides Vasomune with increased financial support and opportunities to pursue further development to address pathological vascular leakage [3]

Oct 28, 2025 8:35 AM Eastern Daylight Time Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community Share A customized program for YMCA of East Tennessee members will include educational series "Wisdom Wednesdays,†and access to Cardio Diagnostics' AI-powered cardiovascular testing at discounted rates from home or during the Heart Health Fair KNOXVILLE, Tenn. & CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, I ...